ArticlePloS one2015
Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review.PharmacoEconomics · 2016Pooled it
- Cost-Effectiveness of Infant Pneumococcal Conjugate Vaccination Strategies in Vietnam: A Stepwise Economic Evaluation.Vaccines · 2026Article
- Cost-effectiveness of a 13-valent pneumococcal conjugate vaccine compared with currently available pneumococcal conjugate vaccines in Indian children.IJID regions · 2025Article
- Economic Evaluation of PHID-CV versus PCV10-SII Compared with no Vaccination in the Philippines.Infectious diseases and therapy · 2025Article
- A Narrative Review of Pneumococcal Conjugate Vaccine Choices for Greater Access and Protection against Pneumococcal Diseases in the Philippines.Acta medica Philippina · 2025Article
- Article
- Outcomes among Thai children with risk conditions hospitalized for pneumococcal disease (invasive or non-bacteraemic pneumonia): A multi-centre, observational study.IJID regions · 2023Article
- A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult.Frontiers in public health · 2023Article
- Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt.Human vaccines & immunotherapeutics · 2022Article
- Estimating the EQ-5D-5L value set for the Philippines.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022Article
- Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries.Applied health economics and health policy · 2022Review
- Advancing sustainable development goals through immunization: a literature review.Globalization and health · 2021Review
- Australia's Role in Pneumococcal and Human Papillomavirus Vaccine Evaluation in Asia-Pacific.Vaccines · 2021Review
- A Narrative Review of Pneumococcal Disease in Children in the Philippines.Infectious diseases and therapy · 2021Review
- Cost-Effectiveness and Budget Impact Analyses of Pneumococcal Vaccination in Indonesia.Journal of environmental and public health · 2021Article
- Epidemiology, Nasopharyngeal Carriage, Serotype Prevalence, and Antibiotic Resistance of Streptococcus pneumoniae in Indonesia.Infectious diseases and therapy · 2020Review
- Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies.Vaccines · 2020Review
- Japanese encephalitis vaccination in the Philippines: A cost-effectiveness analysis comparing alternative delivery strategies.Vaccine · 2020Article
- Value-based tiered pricing for universal health coverage: an idea worth revisiting.Gates open research · 2020Article
- Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeableCost effectiveness and resource allocation : C/E · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe objective of this study is to assess the value for money of introducing pneumococcal conjugate vaccines as part of the immunization program in a lower-middle income country, the Philippines, which is not eligible for GAVI support and lower vaccine prices. It also includes the newest clinical evidence evaluating the efficacy of PCV10, which is lacking in other previous studies.
methodsA cost-utility analysis was conducted. A Markov simulation model was constructed to examine the costs and consequences of PCV10 and PCV13 against the current scenario of no PCV vaccination for a lifetime horizon. A health system perspective was employed to explore different funding schemes, which include universal or partial vaccination coverage subsidized by the government. Results were presented as incremental cost-effectiveness ratios (ICERs) in Philippine peso (Php) per QALY gained (1 USD = 44.20 Php). Probabilistic sensitivity analysis was performed to determine the impact of parameter uncertainty.
resultsWith universal vaccination at a cost per dose of Php 624 for PCV10 and Php 700 for PCV13, both PCVs are cost-effective compared to no vaccination given the ceiling threshold of Php 120,000 per QALY gained, yielding ICERs of Php 68,182 and Php 54,510 for PCV10 and PCV13, respectively. Partial vaccination of 25% of the birth cohort resulted in significantly higher ICER values (Php 112,640 for PCV10 and Php 84,654 for PCV13) due to loss of herd protection. The budget impact analysis reveals that universal vaccination would cost Php 3.87 billion to 4.34 billion per annual, or 1.6 to 1.8 times the budget of the current national vaccination program.
conclusionThe inclusion of PCV in the national immunization program is recommended. PCV13 achieved better value for money compared to PCV10. However, the affordability and sustainability of PCV implementation over the long-term should be considered by decision makers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.